Berlinger Special AG: Doping Sample Security is the Paramount Priority

Food and Healthcare Press Releases Wednesday January 31, 2018 09:52
GANTERSCHWIL, Switzerland--31 Jan--PRNewswire/InfoQuest

The doping samples taken at the coming Olympic Winter Games in PyeongChang, South Korea will be capable of being securely closed and stored. Sample bottle manufacturer Berlinger Special AG is currently assessing any security weaknesses in collaboration and close contact with the World Anti-Doping Agency (WADA) and is also planning additional security measures.

The secure handling and storage of doping samples - at the Olympic Winter Games and in general - is the mission and the goal of sample security bottle manufacturer Berlinger Special AG. In view of this, Berlinger Special AG takes seriously the recent video-documented tests by the team of investigative journalists, even though the testing methods used are not known, and even though their findings contradict the results of the extensive tests conducted both by Berlinger Special AG and by independent specialists on the bottles concerned, which showed in all cases that the bottles worked reliably when correctly handled.

(Photo: https://mma.prnewswire.com/media/635225/Berlinger_Special_AG_Doping_Security.jpg )
(Photo: https://mma.prnewswire.com/media/635224/Berlinger_Special_AG_Doping_Samples.jpg )

What cannot be said of the sample bottles currently used (as is claimed in the film) is that they cannot be distinguished from counterfeits: Berlinger Special AG can always identify its own products beyond any doubt, thanks to a number of secret company-specific features that are integrated into the product.

Improved closing mechanism under consideration

Should security shortcomings be confirmed, Berlinger Special AG will take additional measures to safeguard the samples collected at the coming Olympic Winter Games in PyeongChang. Among the options here, Berlinger Special AG is considering the use of doping sample containers with a modified closing mechanism that cannot be incorrectly handled. Corresponding trials are currently under way, and all the results of these will be made available.

Berlinger Special AG is making every possible effort, in collaboration with WADA and the IOC, to provide secure doping sample solutions that ensure clean competition and credible controls. The results of the current trials, and of any decisions taken in the light thereof, will be communicated without delay.

Further information:
Berlinger Special AG
Media Relations
c/o. KMES Partner I KLAUS
Hans Klaus
Basteiplatz 7
CH-8001 Zurich
Phone: +41-43-544-1744
Email: office@kmespartner.com
Source: Berlinger Special AG

Latest Press Release

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda(R)

People treated with Saxenda(R) (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

Venus Medtech#s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market

China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation...

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

NovoEight(R) Maintains Potency When Stored at 40?C Offering People With Haemophilia A Increased Flexibility in Their Daily Lives

A new long term stability study has shown that haemophilia A treatment NovoEight(R) (turoctocog alfa) remains potent after three months exposure to temperatures of 40ºC.[1] The results were presented today at the WFH 2018 World Congress in Glasgow,...

Related Topics